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Abstract: 
 
The relationship between Guillain-Barré syndrome (GBS) and malignancy is uncertain. 
We retrospectively analyzed data of 118 consecutive patients admitted with GBS from 
Birmingham, U.K. (2001-2012). We calculated relative cancer risk using different definitions 
and determined characteristics of malignancy-associated GBS. Malignancy was globally 
commoner in our GBS cohort compared to the general population (Odds Ratio: 2.08; CI: 
1.06-3.71; p=0.036). However, this was unconfirmed if paraneoplastic criteria were applied. 
GBS patients with cancer were significantly more likely to be older (p=0.043), hyponatremic 
(p=0.037) and demonstrate more axonal loss (p<0.05). Cerebrospinal fluid (CSF) protein 
levels were lower in the malignancy group (p=0.002) and neurological improvement less 
likely (p=0.023). In-patient mortality was significantly higher in patients with malignancy 
(p<0.01). We conclude global cancer risk is higher in GBS than in the general population, 
although definition-dependent. Malignancy requires consideration in elderly, hyponatremic 
subjects with normal CSF protein, severe axonal loss, who fail to improve post-treatment. 
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Introduction. 
 
Guillain-Barré syndrome (GBS) is an acute, frequently post-infective 
polyradiculoneuropathy, occurring after gastrointestinal or respiratory infections. There is 
considerable literature consisting mostly of case reports of GBS described in the context of 
malignancies, although the presence of a definite association is unproven. The association of 
malignancy and GBS without evidence of direct tumor infiltration, was described over 50 
years ago, by Klingon who postulated that the co-occurrence may represent an immune 
response of the peripheral nervous system [1]. However, a common immunopathogenesis 
between GBS and cancer has not to date been demonstrated and no specific onconeural 
antibodies have been identified. To our knowledge, a single population-based study has been 
conducted evaluating the risk of cancer in GBS patients [2]. This analysis from Italy 
described an estimated moderately increased risk of malignancy in GBS, with an odds ratio 
of 2.37 to 2.43. The characteristics of cancer-associated GBS remain uncertain. 
 
Following the recent development in the concept of paraneoplastic peripheral nervous system 
disorders, neuronopathy/neuropathy have been recognized as paraneoplastic manifestation in 
relation to the occurrence of underlying malignancy. In most cases, paraneoplastic 
neurological syndromes can occur months or years before the diagnosis of cancer with 
detection of onconeural antibodies directed against neural antigens expressed by the tumor 
[3]. The definition and diagnostic criteria for paraneoplastic peripheral nervous system 
disorders was proposed by the Paraneoplastic Neurological Syndrome Euronetwork in 2004 
[4]. GBS has been classified as “non-classical paraneoplastic PNS disorder”, in contrast to 
subacute sensory neuronopathy, included as part of the “classical paraneoplastic” disorders. 
With no definite onconeural antibodies identified, diagnosis of GBS in a patient with known 
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cancer classifies as definitely paraneoplastic if it resolves or significantly improves after 
cancer treatment without concomitant immunotherapy. This is not a practical definition as the 
overwhelming majority of patients with GBS are in practice treated with immunotherapy 
before completion of any cancer treatment. The definition of cancer-associated GBS can 
clearly be variable and whether this may impact upon the frequency of the co-existence of the 
2 disorders, appears possible. 
 
The objectives of our study were firstly to retrospectively determine the frequency of co-
occurrence of malignancy in a cohort of patients admitted to our tertiary hospital for GBS 
over a twelve-year period. We aimed to estimate the relative cancer risk in this population as 
well as evaluate the impact of different definitions for cancer-associated GBS. We in 
addition, planned to ascertain the differences in clinical characteristics and outcome between 
GBS patients with and without malignancy, aiming to establish which patients are most at 
risk of associated cancer and therefore likely to benefit from further investigations and 
extended follow-up. 
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Materials and methods 
 
We retrospectively reviewed our institutional data-base for GBS patients admitted between 
2001 and 2012 to our in-patient unit at University Hospitals of Birmingham, United 
Kingdom. Patients with Miller Fisher syndrome (MFS) and subsequently confirmed acute-
onset chronic inflammatory demyelinating polyneuropathy (CIDP) were excluded. Patients 
with incomplete clinical data were also excluded. This study was part of a wider retrospective 
audit on GBS, registered and approved at our institution (CAD- 05169-13, April 2013).  
 
We defined GBS as a clinical diagnosis applying recently proposed diagnostic clinical criteria 
[5]. We classified patients in 2 groups, GBS with malignancy and GBS without malignancy. 
For those with malignancy, we determined the onset of GBS in relation to the diagnosis of 
malignancy. We utilized 2 different definitions for cancer-associated GBS. We first 
considered all cases of cancer diagnosed in the cohort, excluding preceding cancer diagnoses 
>1 year before GBS diagnosis and with no evidence of malignant disease activity at the time 
of GBS diagnosis. Secondly, we also in addition, excluded myelomas and malignancies 
diagnosed >2 years post-GBS onset as per paraneoplastic peripheral nervous system disorder 
criteria [4]. 
 
Patient demographics, duration of inpatient stay, intensive care unit admission, mechanical 
ventilation, Medical Research Council (MRC) sum score (MRCSS) at admission and 
discharge, treatment administered, were ascertained. For patients with cancer, the type of 
malignancy, timing of cancer diagnosis, malignancy status at time of GBS diagnosis, 
treatment administered for GBS, were ascertained. Electrophysiological data as well as 
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biological and immunological data were reviewed. We determined the various features 
observed during admission and the clinical outcome of the patients with and without cancer.  
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Results. 
 
We identified a total of 118 patients admitted to our institution between 2001 and 2012 with a 
clinical diagnosis of GBS. Amongst these, 9 patients were excluded from the analysis due to 
incomplete data.  A total of 12 patients were found to have malignancy. Of those 2 patients 
were immediately excluded, both with breast cancer, who had received this diagnosis 7 and 
20 years, respectively, prior to their GBS and who displayed no evidence of cancer activity or 
progression at the time of the GBS diagnosis. This left an initial total number of associated 
cancers of 10 (9.17% of the cohort). 
 
Considering current definitions of paraneoplastic syndrome [4], we excluded a further 2 
patients who had IgG paraprotein myeloma and an additional 2 patients who had malignancy 
diagnosed >2 years after the GBS presentation. One had prostatic carcinoma and the other a 
basal cell carcinoma, both 4 years after GBS. 
Consequently, a total of 6 patients (5.5% of our total cohort) fulfilled requirements for 
inclusion as malignancy-associated GBS as per existing criteria for paraneoplastic syndrome 
[4]. Amongst these, 3 patients developed malignancy prior to the GBS presentation.  All of 
them had developed GBS while undergoing treatment for their underlying cancer. 
Chemotherapy was not implicated in the development of neuropathy in any of these 3 
patients. Two patients were diagnosed with cancer during their GBS presentation. One patient 
developed cancer one year after the GBS diagnosis. Of the 6 patients whose GBS fulfilled 
criteria for paraneoplastic neurological syndrome, there was one case of angioimmunoblastic 
T-cell lymphoma, one of poorly differentiated squamous cell carcinoma of the nasal septum, 
one of gastric adenocarcinoma, one of hepatocellular carcinoma due to hepatitis B, one of 
rectal carcinoma with liver metastasis and one case of myelodysplastic syndrome.  
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Considering U.K. cancer incidence rates [6], as well as the number of patient years of follow-
up taking into account timing of death, the expected cumulative cancer rate in this GBS 
cohort of 109 patients over the 15-year study period, including the 3 years after admission of 
the last recruited patient (December 2015), was of 4.80 patients. With 10 cancer cases 
considered, the odds ratio was 2.08 (95% CI: 1.06-3.71) and therefore significantly higher 
than expected (p=0.036).  However, considering only the 6 cases meeting the definition for 
paraneoplastic syndrome [4], there was no increased risk of cancer in GBS patients over the 
study period (standardized odds ratio: 1.25; 95% CI: 0.51-2.60; p=0.559). 
 
We analyzed our results considering the 6 cancer cases fulfilling criteria for paraneoplastic 
syndrome. These are summarized in Table 1. Of the 6 patients meeting this definition, 5 were 
males and 1 was female as compared to 70 males and 33 females in the non-malignancy 
group (p=0.66). Average age in the malignancy group was higher compared to the non-
malignancy group (mean of 65.8 [S.D.:13.3] vs. 51.3 years [S.D.:17.5]; p=0.043). None of 
the patients in the malignancy group had positive anti-ganglioside antibodies or antineuronal 
antibodies (anti-Hu, Yo, Ri, CRMP5). There was no difference of lowest forced vital capacity 
(FVC) recorded among both groups (p=0.78). Cerebrospinal fluid (CSF) studies were 
acellular in all cases in both groups. CSF protein levels were significantly lower in patients 
with cancer than in those without cancer (mean: 0.34 g/dL [S.D.: 0.59] vs. mean: 1.37 g/dL 
[S.D.: 1.21]; p=0.002). Hyponatremia was significantly more common amongst patients with 
malignancy (66.7% vs. 23.3%; p=0.037). A higher proportion (3/6; 50%) of the patients in 
the malignancy group required ICU admission with mechanical ventilation compared to of 
those from the non-malignancy group (15/103; 14.6%), this approaching significance 
(p=0.055).  Average length of stay was comparable in both groups (mean of 42.8 days vs. 
23.6 days; p=0.20). Although admission MRCSS were comparable in malignancy and non-
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malignancy groups), improvement during in-patient stay, defined as amelioration of 
admission MRCSS (Medical Research Council Sum Score) was significantly less frequent in 
the malignancy group (p=0.023). From the point of view of electrophysiological subtypes, 3 
patients had acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and 3 had 
axonal GBS, as categorized by new electrodiagnostic criteria [7]. There was no difference in 
the number of patients with different subtypes of GBS in both groups (p=1 for AIDP and 
p=0.66 for axonal GBS). Summated compound muscle action potential (CMAP) was 
significantly lower in the malignancy group (mean: 14.5 mV, S.D.: 10.7 vs. mean: 7.1 mV, 
S.D.: 7.0; p=0.0497).  There was no difference in terms of treatment given to patients in both 
groups with the majority (100% and 91.3% from malignancy and non-malignancy groups, 
respectively), treated with intravenous immunoglobulins. Only 2 of 6 patients (33.3%) with 
malignancy were able to walk at discharge, comparing to 73 of 103 patients (70.9%) without 
malignancy (p=0.075). In-patient mortality was significantly higher in the malignancy group 
compared to the non-malignancy group (33.3% vs. 1%; p=0.0075).  
Considering all 10 cancer cases, the analysis produced similar statistical results with 
significance however not reached for more frequent hyponatremia in patients with 
malignancy (p=0.12) nor for MRC grade improvement during in-patient stay (p=0.10). 
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Discussion. 
 
The relationship between GBS and malignancy has been a topic of controversy since its 
initial descriptions. An earlier report described 2 patients with typical GBS occurring in 
association with Hodgkin’s disease and oat-cell lung carcinoma, without evidence of 
malignant invasion [1]. The likelihood of cancer as a possible precipitating cause of GBS was 
raised, through an immune response towards the peripheral nervous system.  Since then, 
many anecdotal reports relating GBS with various types of malignancy have been published. 
Cases described include malignancy of lung, bladder, blood, colon and skin [2, 8, 9, 10]. One 
major difficulty with previous reports is that some cases appear clearly likely paraneoplastic 
from onset despite a GBS-like presentation, while others, differed with a classical clinical 
GBS presentation, with no associated features to suggest a paraneoplastic phenomenon, 
despite an eventually diagnosed associated malignancy, raising the question about a link 
between the 2. Our patients are not in the first case scenario as all were diagnosed with GBS 
and this remained the final diagnosis at discharge/death. The focus of our study has therefore 
been on the basis of the second eventuality, which is of direct relevance to clinical 
management of patients presenting with GBS. 
 
Paraneoplastic neurological syndromes occur in less than 1% of patients with malignancy [3, 
11]. Many cases present months to years before the diagnosis of cancer
 
[3, 11]. Recent 
developments in concept of paraneoplastic syndrome has led to the inclusion of varieties of 
neuropathies other than the classical paraneoplastic syndromes. Criteria for diagnosis of 
paraneoplastic PNS disorder were adopted from Graus et al., 2004 [4].  Definite 
paraneoplastic disorders of PNS include a classic paraneoplastic syndrome associated with 
cancer and onconeural antibodies. Paraproteinemic neuropathies are not included as 
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paraneoplastic manifestation, although exception to this rule may be made in the case of 
POEMS syndrome, as it is defined [12]. GBS has been considered as one of the “non-
classical paraneoplastic neurological syndromes without onconeuronal antibodies” [13]. 
Since GBS is not a classical PNS and there are no identified onconeuronal antibodies linking 
it to a specific tumor, improvement of the neuropathy following treatment of the tumor is a 
major criterion for diagnosis confirmation. However, most cases would have been treated 
with immunotherapy during the course of illness making the definite diagnosis of 
paraneoplastic syndrome, impossible. 
 
A single population-based study by Vigliani et al. has demonstrated a possible association 
between GBS and cancer [2]. However, the occurrence of GBS in this cohort of patients did 
not meet all the criteria for paraneoplastic syndrome, as were subsequently proposed by 
Graus et al. [4]. In this regard, Vigliani et al. included only malignancies developing or 
recurring 6 months before or after GBS diagnosis [2]. This excludes delayed cancer 
diagnoses, known to occur in some cases years after the neurological presentation. The 
definition used for the association is therefore of major importance in determining the 
existence of a link between the 2 disorders. We here used 2 definitions and confirm a variable 
risk, depending on which one is used. Although cancer in GBS, itself considered as a possible 
non-classical paraneoplastic syndrome [4] appears no more common than cancer in the 
general population, the total number of cancers does appear significantly higher in a cohort of 
patients with a GBS presentation. One reason may be that the definition for paraneoplastic 
neurological disease is too restrictive and wrongly excludes several relevant cases where 
there still may exist a causal relationship between the cancer and the neurological 
presentation, here GBS.  
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The mechanisms of suspected paraneoplastic neuropathies without onconeuronal antibodies 
are unknown. Anti-ganglioside antibodies have been described in some of GBS patients with 
cancer, such as melanoma [14]. GBS encompasses a group of peripheral nerve disorders of 
autoimmune origin with, in axonal forms, evidence supporting the underlying 
pathophysiological mechanism involving the presence of molecular mimicry between 
gangliosides and antigens of an antecedent infection, stimulating a cross-reaction with 
peripheral nerve components [15]. Previous cases have been described of paraneoplastic 
motor neuropathy in patients with anti-GM1 ganglioside antibodies associated with 
epidermoid esophageal carcinoma [16], melanoma [10], bladder [8] and small cell lung 
carcinoma [17, 18]. Whether the detection of anti-gangliosides antibodies may be relevant in 
patients with GBS with malignancy remains however uncertain. It was postulated that the 
expression of gangliosides in the neoplastic tissue may elicit autoimmune responses against 
neural structures [19]. In a case-control study comparing 29 patients with cancer and 
neuropathies with controls, anti-ganglioside antibodies, mainly IgM anti-GM1 were more 
frequently found in patients with cancer [20]. However, the pattern and levels of antibodies 
were not different from those of the controls and it appeared possible that the higher 
occurrence of anti-ganglioside antibodies in cancer patients may relate to a concurrent anti-
tumor immune reaction rather than causative of the neuropathic process. The absence of 
antigangloside antibodies in all cases with cancer in our GBS cohort would similarly plead 
against their implication in the neuropathy. Despite absence of a definite antibody marker, it 
is possible that malignancy-induced immune dysregulation may be implicated in the 
pathogenesis of the acute inflammatory polyradiculoneuropathic process in patients with 
cancer and GBS. 
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Our findings in relation to CSF protein, hyponatremia and electrophysiology are interesting. 
Elevated CSF protein levels are the expression of an inflammatory neural process, and it is 
possible that there may be pathophysiologic differences between the acute 
polyradiculoneuropathy of neoplastic disease and that of typical GBS explaining lower CSF 
protein in patients with malignancy. We unfortunately, in view of the retrospective nature of 
the analysis, do not however have the precise timings of lumbar punctures in many of our 
patients, some having been transferred from local district general hospitals to our center 
during their illness. We were therefore unable to ascertain whether patients with and without 
malignancy had lumbar punctures at comparable times. This is a drawback as early lumbar 
puncture may result in a higher likelihood of normal CSF protein levels. Hyponatremia was 
otherwise found more commonly in patients with malignancy as may have been expected, as 
not uncommon in cancer. In this regard, in view of the mild hyponatremia in the affected 
patients in the current analysis, further testing with serum and urine osmolality did not appear 
to have been performed. We previously found that hyponatremia is non-specific but a likely 
predictor of mortality in GBS [21]. Our current findings interestingly therefore suggest that 
hyponatremia may potentially increase suspicion of an underlying neoplasm in some patients 
with GBS.  Finally, and similarly, more severe electrophysiological axonal loss was more 
frequent in patients affected by malignancy. Whether this may relate to associated pre-
existing asymptomatic neuropathy or to a more severe acute axonopathy, specifically 
occurring in these patients, is unknown. 
 
In conclusion, our findings suggest that there may be an overall excess cancer risk in patients 
with a clinical diagnosis of GBS. Our results are in keeping with only the previous similar 
study performed [2]. The findings appear importantly also dependent on the definition used 
for cancer-associated GBS, and application of the strict published criteria for paraneoplastic 
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syndrome reduced the number of cases and suggested absence of a link. We acknowledge 
that our study is limited by its retrospective design as well as relatively low numbers and that 
the findings therefore need to be considered with caution. However, these results may suggest 
importantly for clinical practice, that consideration of an associated, detectable or occult 
malignancy is warranted in some patients with a clinical presentation of GBS. This is 
particularly relevant in absence of a preceding infectious trigger in older age groups, in 
patients who do not improve as would be expected after treatment, as well as those with 
normal CSF protein, hyponatremia, and severe electrophysiological axonal loss. Our results 
finally raise the issue of adequate investigations which in such cases may justify early use of 
whole-body CT imaging as well as PET. Furthermore, although the long-term monitoring of 
patients with GBS months to years after diagnosis is rare in clinical practice, this may require 
consideration with careful clinical re-assessment for adequate further investigations at regular 
intervals, in selected cases. 
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Table 1: Characteristics of 109 Guillain-Barré syndrome (GBS) patients, from Birmingham, U.K. (2001-
2012) without and with malignancy as per paraneoplastic definitions [4].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 GBS with malignancy GBS without 
malignancy 
P value 
(Fisher Exact 
Test or T-
test) 
Number of patients 6 (5.5%) 103 (94.5%) - 
Mean Age (SD; range) 65.8 years (13.3; 59-
87) 
51.3 years (17.5) p=0.04 
Male: Female ratio 5:1 70:33 p=0.66 
AIDP Subtype 3 47 p=1 
Axonal GBS subtype 3 36 p=0.66 
Length of stay  42.8 days 23.6 days p=0.20 
Hyponatremia 4 (66.7%) 24 (23.3%) p=0.037 
Average CSF protein mean (SD) 0.34 g/L (0.59) 1.37 g/L (1.21) p=0.002 
Lowest FVC 2.61 l 2.87 l p=0.78 
ICU + ventilation 3 (50%) 15 (14.6%) p=0.055 
Treated with immunoglobulins 6 (100%) 94 (91.3%) p=1 
Average CMAP sum score  7.1 mV (7.0) 14.5 mV (10.7) p=0.0497 
Number of patients with 
Improvement in MRCSS  
1 60 p=0.023 
Number of patients able to walk at 
discharge 
2 73 p=0.075 
In-patient mortality 2 (33.3%) 1 (1%) p=0.0075 
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Abstract: 
 
The relationship between Guillain-Barré syndrome (GBS) and malignancy is uncertain. 
We retrospectively analyzed data of 118 consecutive patients admitted with GBS from 
Birmingham, U.K. (2001-2012). We calculated relative cancer risk using different definitions 
and determined characteristics of malignancy-associated GBS. Malignancy was globally 
commoner in our GBS cohort compared to the general population (Odds Ratio: 2.08; CI: 
1.06-3.71; p=0.036). However, this was unconfirmed if paraneoplastic criteria were applied. 
GBS patients with cancer were significantly more likely to be older (p=0.043), hyponatremic 
(p=0.037) and demonstrate more axonal loss (p<0.05). Cerebrospinal fluid (CSF) protein 
levels were lower in the malignancy group (p=0.002) and neurological improvement less 
likely (p=0.023). In-patient mortality was significantly higher in patients with malignancy 
(p<0.01). We conclude global cancer risk is higher in GBS than in the general population, 
although definition-dependent. Malignancy requires consideration in elderly, hyponatremic 
subjects with normal CSF protein, severe axonal loss, who fail to improve post-treatment. 
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Introduction. 
 
Guillain-Barré syndrome (GBS) is an acute, frequently post-infective 
polyradiculoneuropathy, occurring after gastrointestinal or respiratory infections. There is 
considerable literature consisting mostly of case reports of GBS described in the context of 
malignancies, although the presence of a definite association is unproven. The association of 
malignancy and GBS without evidence of direct tumor infiltration, was described over 50 
years ago, by Klingon who postulated that the co-occurrence may represent an immune 
response of the peripheral nervous system [1]. However, a common immunopathogenesis 
between GBS and cancer has not to date been demonstrated and no specific onconeural 
antibodies have been identified. To our knowledge, a single population-based study has been 
conducted evaluating the risk of cancer in GBS patients [2]. This analysis from Italy 
described an estimated moderately increased risk of malignancy in GBS, with an odds ratio 
of 2.37 to 2.43. The characteristics of cancer-associated GBS remain uncertain. 
 
Following the recent development in the concept of paraneoplastic peripheral nervous system 
disorders, neuronopathy/neuropathy have been recognized as paraneoplastic manifestation in 
relation to the occurrence of underlying malignancy. In most cases, paraneoplastic 
neurological syndromes can occur months or years before the diagnosis of cancer with 
detection of onconeural antibodies directed against neural antigens expressed by the tumor 
[3]. The definition and diagnostic criteria for paraneoplastic peripheral nervous system 
disorders was proposed by the Paraneoplastic Neurological Syndrome Euronetwork in 2004 
[4]. GBS has been classified as “non-classical paraneoplastic PNS disorder”, in contrast to 
subacute sensory neuronopathy, included as part of the “classical paraneoplastic” disorders. 
With no definite onconeural antibodies identified, diagnosis of GBS in a patient with known 
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cancer classifies as definitely paraneoplastic if it resolves or significantly improves after 
cancer treatment without concomitant immunotherapy. This is not a practical definition as the 
overwhelming majority of patients with GBS are in practice treated with immunotherapy 
before completion of any cancer treatment. The definition of cancer-associated GBS can 
clearly be variable and whether this may impact upon the frequency of the co-existence of the 
2 disorders, appears possible. 
 
The objectives of our study were firstly to retrospectively determine the frequency of co-
occurrence of malignancy in a cohort of patients admitted to our tertiary hospital for GBS 
over a twelve-year period. We aimed to estimate the relative cancer risk in this population as 
well as evaluate the impact of different definitions for cancer-associated GBS. We in 
addition, planned to ascertain the differences in clinical characteristics and outcome between 
GBS patients with and without malignancy, aiming to establish which patients are most at 
risk of associated cancer and therefore likely to benefit from further investigations and 
extended follow-up. 
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Materials and methods 
 
We retrospectively reviewed our institutional data-base for GBS patients admitted between 
2001 and 2012 to our in-patient unit at University Hospitals of Birmingham, United 
Kingdom. Patients with Miller Fisher syndrome (MFS) and subsequently confirmed acute-
onset chronic inflammatory demyelinating polyneuropathy (CIDP) were excluded. Patients 
with incomplete clinical data were also excluded. This study was part of a wider retrospective 
audit on GBS, registered and approved at our institution (CAD- 05169-13, April 2013).  
 
We defined GBS as a clinical diagnosis applying recently proposed diagnostic clinical criteria 
[5]. We classified patients in 2 groups, GBS with malignancy and GBS without malignancy. 
For those with malignancy, we determined the onset of GBS in relation to the diagnosis of 
malignancy. We utilized 2 different definitions for cancer-associated GBS. We first 
considered all cases of cancer diagnosed in the cohort, excluding preceding cancer diagnoses 
>1 year before GBS diagnosis and with no evidence of malignant disease activity at the time 
of GBS diagnosis. Secondly, we also in addition, excluded myelomas and malignancies 
diagnosed >2 years post-GBS onset as per paraneoplastic peripheral nervous system disorder 
criteria [4]. 
 
Patient demographics, duration of inpatient stay, intensive care unit admission, mechanical 
ventilation, Medical Research Council (MRC) sum score (MRCSS) at admission and 
discharge, treatment administered, were ascertained. For patients with cancer, the type of 
malignancy, timing of cancer diagnosis, malignancy status at time of GBS diagnosis, 
treatment administered for GBS, were ascertained. Electrophysiological data as well as 
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biological and immunological data were reviewed. We determined the various features 
observed during admission and the clinical outcome of the patients with and without cancer.  
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Results. 
 
We identified a total of 118 patients admitted to our institution between 2001 and 2012 with a 
clinical diagnosis of GBS. Amongst these, 9 patients were excluded from the analysis due to 
incomplete data.  A total of 12 patients were found to have malignancy. Of those 2 patients 
were immediately excluded, both with breast cancer, who had received this diagnosis 7 and 
20 years, respectively, prior to their GBS and who displayed no evidence of cancer activity or 
progression at the time of the GBS diagnosis. This left an initial total number of associated 
cancers of 10 (9.17% of the cohort). 
 
Considering current definitions of paraneoplastic syndrome [4], we excluded a further 2 
patients who had IgG paraprotein myeloma and an additional 2 patients who had malignancy 
diagnosed >2 years after the GBS presentation. One had prostatic carcinoma and the other a 
basal cell carcinoma, both 4 years after GBS. 
Consequently, a total of 6 patients (5.5% of our total cohort) fulfilled requirements for 
inclusion as malignancy-associated GBS as per existing criteria for paraneoplastic syndrome 
[4]. Amongst these, 3 patients developed malignancy prior to the GBS presentation.  All of 
them had developed GBS while undergoing treatment for their underlying cancer. 
Chemotherapy was not implicated in the development of neuropathy in any of these 3 
patients. Two patients were diagnosed with cancer during their GBS presentation. One patient 
developed cancer one year after the GBS diagnosis. Of the 6 patients whose GBS fulfilled 
criteria for paraneoplastic neurological syndrome, there was one case of angioimmunoblastic 
T-cell lymphoma, one of poorly differentiated squamous cell carcinoma of the nasal septum, 
one of gastric adenocarcinoma, one of hepatocellular carcinoma due to hepatitis B, one of 
rectal carcinoma with liver metastasis and one case of myelodysplastic syndrome.  
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Considering U.K. cancer incidence rates [6], as well as the number of patient years of follow-
up taking into account timing of death, the expected cumulative cancer rate in this GBS 
cohort of 109 patients over the 15-year study period, including the 3 years after admission of 
the last recruited patient (December 2015), was of 4.80 patients. With 10 cancer cases 
considered, the odds ratio was 2.08 (95% CI: 1.06-3.71) and therefore significantly higher 
than expected (p=0.036).  However, considering only the 6 cases meeting the definition for 
paraneoplastic syndrome [4], there was no increased risk of cancer in GBS patients over the 
study period (standardized odds ratio: 1.25; 95% CI: 0.51-2.60; p=0.559). 
 
We analyzed our results considering the 6 cancer cases fulfilling criteria for paraneoplastic 
syndrome. These are summarized in Table 1. Of the 6 patients meeting this definition, 5 were 
males and 1 was female as compared to 70 males and 33 females in the non-malignancy 
group (p=0.66). Average age in the malignancy group was higher compared to the non-
malignancy group (mean of 65.8 [S.D.:13.3] vs. 51.3 years [S.D.:17.5]; p=0.043). None of 
the patients in the malignancy group had positive anti-ganglioside antibodies or antineuronal 
antibodies (anti-Hu, Yo, Ri, CRMP5). There was no difference of lowest forced vital capacity 
(FVC) recorded among both groups (p=0.78). Cerebrospinal fluid (CSF) studies were 
acellular in all cases in both groups. CSF protein levels were significantly lower in patients 
with cancer than in those without cancer (mean: 0.34 g/dL [S.D.: 0.59] vs. mean: 1.37 g/dL 
[S.D.: 1.21]; p=0.002). Hyponatremia was significantly more common amongst patients with 
malignancy (66.7% vs. 23.3%; p=0.037). A higher proportion (3/6; 50%) of the patients in 
the malignancy group required ICU admission with mechanical ventilation compared to of 
those from the non-malignancy group (15/103; 14.6%), this approaching significance 
(p=0.055).  Average length of stay was comparable in both groups (mean of 42.8 days vs. 
23.6 days; p=0.20). Although admission MRCSS were comparable in malignancy and non-
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malignancy groups), improvement during in-patient stay, defined as amelioration of 
admission MRCSS (Medical Research Council Sum Score) was significantly less frequent in 
the malignancy group (p=0.023). From the point of view of electrophysiological subtypes, 3 
patients had acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and 3 had 
axonal GBS, as categorized by new electrodiagnostic criteria [7]. There was no difference in 
the number of patients with different subtypes of GBS in both groups (p=1 for AIDP and 
p=0.66 for axonal GBS). Summated compound muscle action potential (CMAP) was 
significantly lower in the malignancy group (mean: 14.5 mV, S.D.: 10.7 vs. mean: 7.1 mV, 
S.D.: 7.0; p=0.0497).  There was no difference in terms of treatment given to patients in both 
groups with the majority (100% and 91.3% from malignancy and non-malignancy groups, 
respectively), treated with intravenous immunoglobulins. Only 2 of 6 patients (33.3%) with 
malignancy were able to walk at discharge, comparing to 73 of 103 patients (70.9%) without 
malignancy (p=0.075). In-patient mortality was significantly higher in the malignancy group 
compared to the non-malignancy group (33.3% vs. 1%; p=0.0075).  
Considering all 10 cancer cases, the analysis produced similar statistical results with 
significance however not reached for more frequent hyponatremia in patients with 
malignancy (p=0.12) nor for MRC grade improvement during in-patient stay (p=0.10). 
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Discussion. 
 
The relationship between GBS and malignancy has been a topic of controversy since its 
initial descriptions. An earlier report described 2 patients with typical GBS occurring in 
association with Hodgkin’s disease and oat-cell lung carcinoma, without evidence of 
malignant invasion [1]. The likelihood of cancer as a possible precipitating cause of GBS was 
raised, through an immune response towards the peripheral nervous system.  Since then, 
many anecdotal reports relating GBS with various types of malignancy have been published. 
Cases described include malignancy of lung, bladder, blood, colon and skin [2, 8, 9, 10]. One 
major difficulty with previous reports is that some cases appear clearly likely paraneoplastic 
from onset despite a GBS-like presentation, while others, differed with a classical clinical 
GBS presentation, with no associated features to suggest a paraneoplastic phenomenon, 
despite an eventually diagnosed associated malignancy, raising the question about a link 
between the 2. Our patients are not in the first case scenario as all were diagnosed with GBS 
and this remained the final diagnosis at discharge/death. The focus of our study has therefore 
been on the basis of the second eventuality, which is of direct relevance to clinical 
management of patients presenting with GBS. 
 
Paraneoplastic neurological syndromes occur in less than 1% of patients with malignancy [3, 
11]. Many cases present months to years before the diagnosis of cancer
 
[3, 11]. Recent 
developments in concept of paraneoplastic syndrome has led to the inclusion of varieties of 
neuropathies other than the classical paraneoplastic syndromes. Criteria for diagnosis of 
paraneoplastic PNS disorder were adopted from Graus et al., 2004 [4].  Definite 
paraneoplastic disorders of PNS include a classic paraneoplastic syndrome associated with 
cancer and onconeural antibodies. Paraproteinemic neuropathies are not included as 
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paraneoplastic manifestation, although exception to this rule may be made in the case of 
POEMS syndrome, as it is defined [12]. GBS has been considered as one of the “non-
classical paraneoplastic neurological syndromes without onconeuronal antibodies” [13]. 
Since GBS is not a classical PNS and there are no identified onconeuronal antibodies linking 
it to a specific tumor, improvement of the neuropathy following treatment of the tumor is a 
major criterion for diagnosis confirmation. However, most cases would have been treated 
with immunotherapy during the course of illness making the definite diagnosis of 
paraneoplastic syndrome, impossible. 
 
A single population-based study by Vigliani et al. has demonstrated a possible association 
between GBS and cancer [2]. However, the occurrence of GBS in this cohort of patients did 
not meet all the criteria for paraneoplastic syndrome, as were subsequently proposed by 
Graus et al. [4]. In this regard, Vigliani et al. included only malignancies developing or 
recurring 6 months before or after GBS diagnosis [2]. This excludes delayed cancer 
diagnoses, known to occur in some cases years after the neurological presentation. The 
definition used for the association is therefore of major importance in determining the 
existence of a link between the 2 disorders. We here used 2 definitions and confirm a variable 
risk, depending on which one is used. Although cancer in GBS, itself considered as a possible 
non-classical paraneoplastic syndrome [4] appears no more common than cancer in the 
general population, the total number of cancers does appear significantly higher in a cohort of 
patients with a GBS presentation. One reason may be that the definition for paraneoplastic 
neurological disease is too restrictive and wrongly excludes several relevant cases where 
there still may exist a causal relationship between the cancer and the neurological 
presentation, here GBS.  
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The mechanisms of suspected paraneoplastic neuropathies without onconeuronal antibodies 
are unknown. Anti-ganglioside antibodies have been described in some of GBS patients with 
cancer, such as melanoma [14]. GBS encompasses a group of peripheral nerve disorders of 
autoimmune origin with, in axonal forms, evidence supporting the underlying 
pathophysiological mechanism involving the presence of molecular mimicry between 
gangliosides and antigens of an antecedent infection, stimulating a cross-reaction with 
peripheral nerve components [15]. Previous cases have been described of paraneoplastic 
motor neuropathy in patients with anti-GM1 ganglioside antibodies associated with 
epidermoid esophageal carcinoma [16], melanoma [10], bladder [8] and small cell lung 
carcinoma [17, 18]. Whether the detection of anti-gangliosides antibodies may be relevant in 
patients with GBS with malignancy remains however uncertain. It was postulated that the 
expression of gangliosides in the neoplastic tissue may elicit autoimmune responses against 
neural structures [19]. In a case-control study comparing 29 patients with cancer and 
neuropathies with controls, anti-ganglioside antibodies, mainly IgM anti-GM1 were more 
frequently found in patients with cancer [20]. However, the pattern and levels of antibodies 
were not different from those of the controls and it appeared possible that the higher 
occurrence of anti-ganglioside antibodies in cancer patients may relate to a concurrent anti-
tumor immune reaction rather than causative of the neuropathic process. The absence of 
antigangloside antibodies in all cases with cancer in our GBS cohort would similarly plead 
against their implication in the neuropathy. Despite absence of a definite antibody marker, it 
is possible that malignancy-induced immune dysregulation may be implicated in the 
pathogenesis of the acute inflammatory polyradiculoneuropathic process in patients with 
cancer and GBS. 
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Our findings in relation to CSF protein, hyponatremia and electrophysiology are interesting. 
Elevated CSF protein levels are the expression of an inflammatory neural process, and it is 
possible that there may be pathophysiologic differences between the acute 
polyradiculoneuropathy of neoplastic disease and that of typical GBS explaining lower CSF 
protein in patients with malignancy. We unfortunately, in view of the retrospective nature of 
the analysis, do not however have the precise timings of lumbar punctures in many of our 
patients, some having been transferred from local district general hospitals to our center 
during their illness. We were therefore unable to ascertain whether patients with and without 
malignancy had lumbar punctures at comparable times. This is a drawback as early lumbar 
puncture may result in a higher likelihood of normal CSF protein levels. Hyponatremia was 
otherwise found more commonly in patients with malignancy as may have been expected, as 
not uncommon in cancer. In this regard, in view of the mild hyponatremia in the affected 
patients in the current analysis, further testing with serum and urine osmolality did not appear 
to have been performed. We previously found that hyponatremia is non-specific but a likely 
predictor of mortality in GBS [21]. Our current findings interestingly therefore suggest that 
hyponatremia may potentially increase suspicion of an underlying neoplasm in some patients 
with GBS.  Finally, and similarly, more severe electrophysiological axonal loss was more 
frequent in patients affected by malignancy. Whether this may relate to associated pre-
existing asymptomatic neuropathy or to a more severe acute axonopathy, specifically 
occurring in these patients, is unknown. 
 
In conclusion, our findings suggest that there may be an overall excess cancer risk in patients 
with a clinical diagnosis of GBS. Our results are in keeping with only the previous similar 
study performed [2]. The findings appear importantly also dependent on the definition used 
for cancer-associated GBS, and application of the strict published criteria for paraneoplastic 
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syndrome reduced the number of cases and suggested absence of a link. We acknowledge 
that our study is limited by its retrospective design as well as relatively low numbers and that 
the findings therefore need to be considered with caution. However, these results may suggest 
importantly for clinical practice, that consideration of an associated, detectable or occult 
malignancy is warranted in some patients with a clinical presentation of GBS. This is 
particularly relevant in absence of a preceding infectious trigger in older age groups, in 
patients who do not improve as would be expected after treatment, as well as those with 
normal CSF protein, hyponatremia, and severe electrophysiological axonal loss. Our results 
finally raise the issue of adequate investigations which in such cases may justify early use of 
whole-body CT imaging as well as PET. Furthermore, although the long-term monitoring of 
patients with GBS months to years after diagnosis is rare in clinical practice, this may require 
consideration with careful clinical re-assessment for adequate further investigations at regular 
intervals, in selected cases. 
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Table 1: Characteristics of 109 Guillain-Barré syndrome (GBS) patients, from Birmingham, U.K. (2001-
2012) without and with malignancy as per paraneoplastic definitions [4].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 GBS with malignancy GBS without 
malignancy 
P value 
(Fisher Exact 
Test or T-
test) 
Number of patients 6 (5.5%) 103 (94.5%) - 
Mean Age (SD; range) 65.8 years (13.3; 59-
87) 
51.3 years (17.5) p=0.04 
Male: Female ratio 5:1 70:33 p=0.66 
AIDP Subtype 3 47 p=1 
Axonal GBS subtype 3 36 p=0.66 
Length of stay  42.8 days 23.6 days p=0.20 
Hyponatremia 4 (66.7%) 24 (23.3%) p=0.037 
Average CSF protein mean (SD) 0.34 g/L (0.59) 1.37 g/L (1.21) p=0.002 
Lowest FVC 2.61 l 2.87 l p=0.78 
ICU + ventilation 3 (50%) 15 (14.6%) p=0.055 
Treated with immunoglobulins 6 (100%) 94 (91.3%) p=1 
Average CMAP sum score  7.1 mV (7.0) 14.5 mV (10.7) p=0.0497 
Number of patients with 
Improvement in MRCSS  
1 60 p=0.023 
Number of patients able to walk at 
discharge 
2 73 p=0.075 
In-patient mortality 2 (33.3%) 1 (1%) p=0.0075 
